BACKGROUND: Glucagon-like peptide-1 (GLP-1) is a gut-derived incretin hormone that stimulates insulin secretion, cellular glucose uptake, and has immune-regulatory functions. Glucagon-like peptide-1 is markedly altered after trauma and sepsis, but the implications remain unclear. STUDY DESIGN: We performed an analysis of a prospective, longitudinal cohort study of critically ill surgical patients with sepsis. Patient characteristics and clinical data were collected, as well as peripheral blood sampling for biomarker analysis, out to 28 days after sepsis onset. We prospectively adjudicated sepsis diagnosis, severity, clinical outcomes, and 6-month follow-up. RESULTS: The cohort included 157 septic surgical patients with significant physiologic derangement (Maximum Sequential Organ Failure Assessment [SOFA] score 8, interquartile range [IQR] 4 to 11), a high rate of multiple organ failure (50.3%), and septic shock (24.2%). Despite high disease severity, both early death (<14 days; n = 4, 2.9%) and overall inpatient mortality were low (n = 12, 7.6%). However, post-discharge 6-month mortality was nearly 3-fold higher (19.7%). Both GLP-1 and interleukin [IL]-6 levels were significantly elevated for 21 days (p ≤ 0.01) in patients who developed chronic critical illness (CCI) compared with patients with a rapid recovery. Elevated GLP-1 at 24 hours was a significant independent predictor for the development of CCI after controlling for IL-6 and glucose levels (p = 0.027), and at day 14 for death or severe functional disability at 6 months (WHO/Zubrod score 4-5, p = 0.014). CONCLUSIONS: Elevated GLP-1 within 24 hours of sepsis is a predictor of early death or persistent organ dysfunction. Among early survivors, persistently elevated GLP-1 levels at day 14 are strongly predictive of death or severe functional disability at 6 months. Persistently elevated GLP-1 levels may be a marker of a nonresolving catabolic state that is associated with muscle wasting and dismal outcomes after sepsis and chronic critical illness.
BACKGROUND:Glucagon-like peptide-1 (GLP-1) is a gut-derived incretin hormone that stimulates insulin secretion, cellular glucose uptake, and has immune-regulatory functions. Glucagon-like peptide-1 is markedly altered after trauma and sepsis, but the implications remain unclear. STUDY DESIGN: We performed an analysis of a prospective, longitudinal cohort study of critically ill surgical patients with sepsis. Patient characteristics and clinical data were collected, as well as peripheral blood sampling for biomarker analysis, out to 28 days after sepsis onset. We prospectively adjudicated sepsis diagnosis, severity, clinical outcomes, and 6-month follow-up. RESULTS: The cohort included 157 septic surgical patients with significant physiologic derangement (Maximum Sequential Organ Failure Assessment [SOFA] score 8, interquartile range [IQR] 4 to 11), a high rate of multiple organ failure (50.3%), and septic shock (24.2%). Despite high disease severity, both early death (<14 days; n = 4, 2.9%) and overall inpatient mortality were low (n = 12, 7.6%). However, post-discharge 6-month mortality was nearly 3-fold higher (19.7%). Both GLP-1 and interleukin [IL]-6 levels were significantly elevated for 21 days (p ≤ 0.01) in patients who developed chronic critical illness (CCI) compared with patients with a rapid recovery. Elevated GLP-1 at 24 hours was a significant independent predictor for the development of CCI after controlling for IL-6 and glucose levels (p = 0.027), and at day 14 for death or severe functional disability at 6 months (WHO/Zubrod score 4-5, p = 0.014). CONCLUSIONS: Elevated GLP-1 within 24 hours of sepsis is a predictor of early death or persistent organ dysfunction. Among early survivors, persistently elevated GLP-1 levels at day 14 are strongly predictive of death or severe functional disability at 6 months. Persistently elevated GLP-1 levels may be a marker of a nonresolving catabolic state that is associated with muscle wasting and dismal outcomes after sepsis and chronic critical illness.
Authors: G van den Berghe; P Wouters; F Weekers; C Verwaest; F Bruyninckx; M Schetz; D Vlasselaers; P Ferdinande; P Lauwers; R Bouillon Journal: N Engl J Med Date: 2001-11-08 Impact factor: 91.245
Authors: Mitchell M Levy; Mitchell P Fink; John C Marshall; Edward Abraham; Derek Angus; Deborah Cook; Jonathan Cohen; Steven M Opal; Jean-Louis Vincent; Graham Ramsay Journal: Crit Care Med Date: 2003-04 Impact factor: 7.598
Authors: Michael A Nauck; Markus M Heimesaat; Kai Behle; Jens J Holst; Markus S Nauck; Robert Ritzel; Michael Hüfner; Wolff H Schmiegel Journal: J Clin Endocrinol Metab Date: 2002-03 Impact factor: 5.958
Authors: Grant V Bochicchio; Jin Sung; Manjari Joshi; Kelly Bochicchio; Steven B Johnson; Walter Meyer; Thomas M Scalea Journal: J Trauma Date: 2005-05
Authors: Greet Van den Berghe; Pieter J Wouters; Roger Bouillon; Frank Weekers; Charles Verwaest; Miet Schetz; Dirk Vlasselaers; Patrick Ferdinande; Peter Lauwers Journal: Crit Care Med Date: 2003-02 Impact factor: 7.598
Authors: Hiroshi Yamamoto; Charlotte E Lee; Jacob N Marcus; Todd D Williams; J Michael Overton; Marisol E Lopez; Anthony N Hollenberg; Laurie Baggio; Clifford B Saper; Daniel J Drucker; Joel K Elmquist Journal: J Clin Invest Date: 2002-07 Impact factor: 14.808
Authors: Michael C Cox; Scott C Brakenridge; Julie A Stortz; Russell B Hawkins; Dijoa B Darden; Gabriela L Ghita; Alicia M Mohr; Lyle L Moldawer; Philip A Efron; Frederick A Moore Journal: Am J Surg Date: 2020-07-25 Impact factor: 2.565
Authors: Gwendolyn Vliegen; Kaat Kehoe; An Bracke; Emilie De Hert; Robert Verkerk; Erik Fransen; Bart 's Jongers; Esther Peters; Anne-Marie Lambeir; Samir Kumar-Singh; Peter Pickkers; Philippe G Jorens; Ingrid De Meester Journal: PLoS One Date: 2020-04-21 Impact factor: 3.240
Authors: Dijoia B Darden; Xiaoru Dong; Maigan A Brusko; Lauren Kelly; Brittany Fenner; Jaimar C Rincon; Marvin L Dirain; Ricardo Ungaro; Dina C Nacionales; Marie Gauthier; Michael Kladde; Todd M Brusko; Azra Bihorac; Frederick A Moore; Tyler Loftus; Rhonda Bacher; Lyle L Moldawer; Alicia M Mohr; Philip A Efron Journal: Front Immunol Date: 2021-08-16 Impact factor: 7.561
Authors: Robert T Mankowski; Stephen D Anton; Gabriela L Ghita; Babette Brumback; Dijoia B Darden; Azra Bihorac; Christiaan Leeuwenburgh; Lyle L Moldawer; Philip A Efron; Scott C Brakenridge; Frederick A Moore Journal: J Gerontol A Biol Sci Med Sci Date: 2022-01-07 Impact factor: 6.591
Authors: Kendall R McEachron; Yi Yang; James S Hodges; Gregory J Beilman; Timothy L Pruett; Varvara A Kirchner; Ty B Dunn; Martin L Freeman; Guru Trikudanathan; Kristine E Mulier; Peggy Ptacek; Melena D Bellin Journal: Pancreas Date: 2020-07 Impact factor: 3.243